No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
695 |
4. Check minimum number of eventsNone |
695 |
5. Include endpointsNone |
695 |
6. Filter based on genotype QC (FinnGen only) |
695 |
Control definitions (FinnGen only)
- Control exclude
- G6_NEURODEG
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF6
- Parent code in ICD-10
- G31
- Name in latin
- Atrophia cerebri circumscripta
Similar endpoints
↥List of similar endpoints to
Circumscribed brain atrophy
based on the number of shared cases.
Similar with more cases:
- Degenerative diseases of the nervous system
- Other degenerative diseases of the nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 9185 | 4538 | 4462 |
| Only index persons | 6588 | 3580 | 3008 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.13 | 0.13 | 0.12 |
| Only index persons | 0.12 | 0.13 | 0.11 |
| Median age at first event (years) | |||
| Whole population | 66.45 | 69.56 | 63.74 |
| Only index persons | 69.18 | 70.86 | 67.17 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 695 | 301 | 394 |
| Unadjusted period prevalence (%) | 0.14 | 0.10 | 0.17 |
| Median age at first event (years) | 67.86 | 68.78 | 67.15 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 603
- Matched controls
- 6027
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G31.0
ICD-10 Finland
Circumscribed brain atrophy
10351.2
323.0
409
*
F02.09*G31.0
ICD-10 Finland
Dementia in Pick's disease without information on additional symptoms
+∞
126.6
117
*
34791
ICD-8 Finland
Other disease of brain, Atrophia cerebri
+∞
109.8
102
*
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
11.3
99.5
207
267
F03
ICD-10 Finland
Unspecified dementia
14.6
82.0
145
128
N05AX08
ATC
risperidone; systemic
11.2
79.2
161
190
TAB00
NOMESCO Finland
Lumbar puncture
17.6
73.0
118
82
N05AH04
ATC
quetiapine; oral
6.7
65.8
191
388
XA800
NOMESCO Finland
Neuropsychological investigation
16.0
64.5
108
81
N06DX01
ATC
memantine; oral
12.3
49.7
93
88
N06DA02
ATC
donepezil; oral
13.4
48.5
87
75
P20
ICPC
Memory disturbance
5.0
46.8
173
448
N05AH03
ATC
olanzapine; systemic
10.8
46.5
93
100
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.5
45.4
115
184
N03AG01
ATC
valproic acid; systemic, rectal
8.0
42.6
102
149
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
436.0
41.7
41
*
A28
ICPC
Limited function/disability NOS
3.7
35.1
188
664
G30.1
ICD-10 Finland
Alzheimer disease with late onset
13.7
34.9
61
49
P70
ICPC
Dementia
19.2
34.7
53
30
F02.09
ICD-10 Finland
Dementia in Pick's disease without information on additional symptoms
329.1
31.1
31
*
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
17.9
30.7
48
29
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.9
30.5
90
173
G30.9
ICD-10 Finland
Alzheimer disease, unspecified
35.7
29.0
37
11
G30.0
ICD-10 Finland
Alzheimer disease with early onset
294.5
28.0
28
*
F06.7
ICD-10 Finland
Mild cognitive disorder
10.0
27.1
55
60
N06AX11
ATC
mirtazapine; oral
2.7
26.1
234
1138
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
271.6
25.9
26
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
5.2
25.3
83
180
N05BA04
ATC
oxazepam; oral
2.9
24.9
189
827
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.5
23.2
72
146
N06DA03
ATC
rivastigmine; oral, transdermal
9.1
23.1
49
58
N05BA06
ATC
lorazepam; systemic, sublingual
5.4
22.6
70
142
N06AB10
ATC
escitalopram; oral
3.3
21.7
125
448
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
31.3
20.7
27
9
R47.0
ICD-10 Finland
Dysphasia and aphasia
17.1
19.8
31
19
AA1AD
NOMESCO Finland
CT of head and brain
2.5
19.7
201
1018
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
6.7
19.1
49
78
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
4.2
18.9
76
202
G31.2
ICD-10 Finland
Degeneration of nervous system due to alcohol
+∞
18.8
18
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.5
18.3
67
163
F0203, G310
ICD-10 Finland
NA
+∞
17.8
17
*
SPAT1216
SPAT
Assessment of functional ability
2.7
17.7
144
637
R41.3
ICD-10 Finland
Other amnesia
6.2
17.3
47
81
IGY02
NOMESCO Finland
Psychiatric monitoring contact
16.6
17.2
27
17
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
14.6
16.9
28
20
N19
ICPC
Speech disorder
11.6
16.9
31
28
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.7
16.7
76
225
R41.0
ICD-10 Finland
Disorientation, unspecified
5.9
16.4
46
83
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.1
16.4
45
79
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.2
16.1
89
306
N05AD01
ATC
haloperidol; systemic
5.8
16.1
46
85
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.1
15.5
226
1324
N06AX16
ATC
venlafaxine; oral
3.3
15.1
79
261
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.4
15.0
76
245
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
14.9
146
708
F0204, G310
ICD-10 Finland
NA
+∞
14.6
14
*
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
15.9
14.5
23
15
F29
ICD-10 Finland
Unspecified nonorganic psychosis
8.1
14.0
31
40
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
18.1
13.9
21
12
R53
ICD-10 Finland
Malaise and fatigue
2.3
13.8
154
791
G31.1
ICD-10 Finland
Senile degeneration of brain, not elsewhere classified
+∞
13.6
13
*
F0200, G310
ICD-10 Finland
NA
+∞
13.6
13
*
A06AD11
ATC
lactulose; oral
2.3
13.2
136
672
N06AB04
ATC
citalopram; systemic
2.3
13.0
143
731
G31
ICD-10 Finland
Other degenerative diseases of nervous system, not elsewhere classified
+∞
12.5
12
*
IGY99
NOMESCO Finland
Other psychiatric treatment contact
13.7
12.0
20
15
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
6.7
12.0
30
47
IAB14
NOMESCO Finland
Geriatric psychiatry consultation
30.7
11.7
15
5
RT150
NOMESCO Finland
NA
+∞
11.5
11
*
F00.00*G30.0
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, presenile onset without additional symptoms
+∞
11.5
11
*
A04
ICPC
Weakness/tiredness general
2.5
11.5
96
426
S01.0
ICD-10 Finland
Open wound of scalp
3.0
11.4
67
241
F05.9
ICD-10 Finland
Delirium, unspecified
6.1
11.3
30
51
N03AE01
ATC
clonazepam; systemic
3.4
11.3
56
178
SPAT1053
SPAT
Memory test
2.2
11.2
129
666
G12.2
ICD-10 Finland
Motor neuron disease
14.2
11.0
18
13
N03AX09
ATC
lamotrigine; oral
5.1
10.8
33
67
P28
ICPC
Limited function/disability (P)
21.9
10.7
15
7
R4130
NOMESCO Finland
Speech therapy
5.7
10.7
30
55
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.0
10.7
63
227
AA5DR
NOMESCO Finland
Brain metabolism PET with CT
61.1
10.7
12
*
RT250
NOMESCO Finland
NA
61.1
10.7
12
*
IBZ07
NOMESCO Finland
Neurological assessment in psychiatry
61.1
10.7
12
*
N99
ICPC
Neurological disease other
8.7
10.6
22
26
F22.0
ICD-10 Finland
Delusional disorder
9.4
10.6
21
23
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
14.5
10.5
17
12
N05BA01
ATC
diazepam; systemic, rectal
2.4
10.5
99
463
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
12.3
10.4
18
15
G30
ICD-10 Finland
Alzheimer disease
23.8
10.3
14
6
F80.1
ICD-10 Finland
Expressive language disorder
23.8
10.3
14
6
P99
ICPC
Psychological disorders other
7.7
10.3
23
31
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.4
9.9
47
145
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
10.9
9.8
18
17
U04
ICPC
Incontinence urine
3.5
9.7
44
131
W19
ICD-10 Finland
Unspecified fall
2.6
9.7
71
292
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
15.3
9.6
15
10
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
5.1
9.5
29
59
P29
ICPC
Psychological sympt/compl other
4.4
9.4
33
78
F0202, G310
ICD-10 Finland
NA
+∞
9.4
9
*
F064, G310
ICD-10 Finland
NA
+∞
9.4
9
*
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
3.7
9.3
40
114
183
Kela drug reimbursment
Lamotrigin and topiramate
10.9
9.3
17
16
L28
ICPC
Limited function/disability (L)
2.0
9.1
119
647
G40
ICD-10 Finland
Epilepsy
10.3
9.1
17
17
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
0.4
9.0
44
968
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.8
8.9
183
1168
N05CF01
ATC
zopiclone; oral
1.7
8.8
219
1487
F33.30
ICD-10 Finland
Recurrent depression, severe episode without somatic syndrome
14.3
8.7
14
10
F06.4
ICD-10 Finland
Organic anxiety disorder
50.7
8.7
10
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.2
8.6
44
144
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
3.2
8.6
44
144
78020
ICD-8 Finland
Certain symptoms referable to nervous system and special senses, Convulsions
10.2
8.6
16
16
N05AX12
ATC
aripiprazole; systemic
6.6
8.5
21
33
SPAT1254
SPAT
Administration of medicine
2.1
8.4
103
544
WYA20
NOMESCO Finland
Home visit
6.9
8.4
20
30
A29
ICPC
General symptom/complaint other
2.2
8.4
84
406
F0201, G310
ICD-10 Finland
NA
+∞
8.3
8
*
F0633, G310
ICD-10 Finland
NA
+∞
8.3
8
*
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
7.2
8.3
19
27
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
6.2
8.2
21
35
IER02
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, group
22.4
8.0
11
5
P98
ICPC
Psychosis NOS/other
22.4
8.0
11
5
N05AB03
ATC
perphenazine; systemic, rectal
4.3
7.9
28
68
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.7
7.8
51
197
34599
ICD-8 Finland
Epilepsy, Other and unspecified
15.3
7.7
12
8
IFB01
NOMESCO Finland
Electroconvulsive Therapy (ECT)
45.6
7.7
9
*
Z03.2
ICD-10 Finland
Observation for suspected mental and behavioural disorders
12.0
7.6
13
11
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
5.9
7.6
20
35
F00.20*G30.8
ICD-10 Finland
Dementia in Alzheimer's disease, atypical or mixed type without additional symptoms
9.0
7.6
15
17
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.0
7.6
111
625
F61.0
ICD-10 Finland
Mixed personality disorders
10.2
7.6
14
14
SPAT1234
SPAT
Support of social functional capacity
2.8
7.4
45
167
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.3
7.4
26
63
F02.00
ICD-10 Finland
Dementia in Pick's disease without additional symptoms
+∞
7.3
7
*
F062, G310
ICD-10 Finland
NA
+∞
7.3
7
*
S06.0
ICD-10 Finland
Concussion
2.3
7.3
69
323
Z03
ICPC
Housing/neighbourhood problem
16.0
7.2
11
7
IAB01
NOMESCO Finland
Psychiatric pharmacotherapy consultation
16.0
7.2
11
7
N05AF03
ATC
chlorprothixene; systemic
4.9
7.2
22
46
N06AX26
ATC
vortioxetine; oral
3.8
7.2
29
80
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
6.7
7.2
17
26
N06AB06
ATC
sertraline; oral
2.5
7.1
53
221
R55
ICD-10 Finland
Syncope and collapse
2.1
7.1
81
414
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.0
7.0
93
507
N28
ICPC
Limited function/disability (N)
5.3
7.0
20
39
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.0
7.0
38
132
N05AH02
ATC
clozapine; systemic
7.7
6.9
15
20
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
8.4
6.9
14
17
N06AX12
ATC
bupropion; oral
3.9
6.8
26
68
IGV01
NOMESCO Finland
Psychiatric network contact
40.5
6.8
8
*
IER04
NOMESCO Finland
Rehabilitative psychiatric group intervention, functional
16.9
6.8
10
6
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.0
6.7
92
506
AA400
NOMESCO Finland
Electroconvulsive therapy
22.8
6.7
9
*
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
6.0
6.6
17
29
SPAT1229
SPAT
Assessment of need for aid
2.2
6.6
67
327
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
10.2
6.6
12
12
F00, F03
ICD-10 Finland
NA
70.6
6.4
7
*
N05AF05
ATC
zuclopenthixol; systemic
8.3
6.4
13
16
N05CD07
ATC
temazepam; oral
1.9
6.3
100
579
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.9
6.3
93
526
P74
ICPC
Anxiety disorder/anxiety state
4.4
6.3
21
49
F22.9
ICD-10 Finland
Persistent delusional disorder, unspecified
18.2
6.3
9
5
F06.32
ICD-10 Finland
Organic depression
18.2
6.3
9
5
3454A
ICD-9 Finland
Epilepsy, Partial epilepsy, with impairment of consciousness[EPILEPSIA GENERALISATA SECUNDARIA]
+∞
6.3
6
*
F060, G310
ICD-10 Finland
NA
+∞
6.3
6
*
F020, G310
ICD-10 Finland
NA
+∞
6.3
6
*
N03AF01
ATC
carbamazepine; oral, rectal
2.6
6.2
42
167
G30.8
ICD-10 Finland
Other Alzheimer disease
7.1
6.2
14
20
N05AA02
ATC
levomepromazine; systemic
3.1
6.2
31
102
P72
ICPC
Schizophrenia
6.4
6.2
15
24
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
4.7
6.1
19
41
N05BE01
ATC
buspirone; oral
4.2
6.1
21
51
P01
ICPC
Feeling anxious/nervous/tense
2.9
6.1
35
126
79199
ICD-8 Finland
Headache
5.3
6.0
17
33
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
93
28
38.19
148.07
1.0
1.0
37.4
26.1
ng/l
1.58
74
11
92
28
37.72
145.99
1.0
1.0
824.9
682.8
ng/l
0.74
71
12
91
28
37.25
143.91
1.0
1.0
292.7
197.9
ng/l
3.03
74
11
78
58
15.02
84.84
5.6
4.1
314.7
352.1
umol/l
0.96
66
50
90
95
10.73
78.26
1.2
1.3
2.9
67.5
e6/l
0.63
66
75
89
95
10.60
76.74
1.2
1.4
1003.9
1346.4
e6/l
0.11
69
77
236
1233
2.38
24.13
2.0
1.8
1184.3
1181.1
nmol/l
0.02
187
920
22
41
5.51
11.41
1.1
1.0
—
—
—
0
0
340
2472
1.73
11.34
2.4
2.1
91.1
94.0
pmol/l
0.58
188
1269
89
418
2.30
10.92
1.9
1.7
1.5
1.6
%
0.53
78
348
23
50
4.72
10.07
1.1
1.0
—
—
—
0
0
20
46
4.45
8.19
1.1
1.0
—
—
—
0
0
175
1143
1.71
8.07
2.9
3.3
2.4
2.5
mmol/l
2.10
137
999
429
5014
0.62
8.02
3.8
4.8
1.4
1.4
mmol/l
0.96
379
4485
124
740
1.82
7.79
1.9
1.8
—
—
—
0
0
123
736
1.82
7.65
1.9
1.8
—
—
—
0
0
12
9
13.54
7.40
17.9
14.0
1316.8
1673.7
nmol/l
—
12
9
263
1939
1.57
7.36
2.5
3.6
2.3
2.3
mmol/l
0.74
218
1662
158
1039
1.67
7.01
1.9
1.8
—
—
—
0
0
417
4854
0.65
6.94
3.4
4.3
1.3
1.3
mmol/l
0.88
358
4310
440
5058
0.65
6.82
3.9
4.9
4.5
4.5
mmol/l
0.36
389
4565
11
9
12.39
6.60
14.2
10.6
622.1
955.2
nmol/l
—
11
9
455
5179
0.65
6.52
4.6
5.5
2.6
2.6
mmol/l
0.41
403
4649
241
1789
1.53
6.33
2.8
2.1
895.6
248.1
u/l
0.53
228
1676
429
4920
0.67
6.08
5.8
6.6
39.8
41.0
mmol/mol
2.08
396
4467
427
4899
0.67
6.03
17.6
16.2
77.8
72.9
ml/min/173m2
5.89
338
4081
132
1925
0.61
5.99
3.2
4.1
4.0
9.3
mg/mmol
4.35
88
1229
204
1488
1.53
5.72
1.7
1.6
20.6
20.5
nmol/l
0.03
188
1236
316
2523
1.46
5.64
3.7
4.9
35.2
34.7
g/l
0.89
284
2339
74
416
1.87
5.59
1.9
1.6
—
—
—
0
0
12
25
4.87
5.51
1.0
1.0
1.0
1.1
u/l
—
5
15
328
2690
1.42
4.82
5.6
6.1
1.2
1.2
mmol/l
1.50
300
2422
352
2923
1.41
4.81
5.8
7.0
1.2
1.2
mmol/l
3.53
300
2462
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
11
24
4.64
4.79
1.0
1.2
—
—
—
0
0
130
1823
0.65
4.75
2.5
3.2
7.4
7.2
mmol/l
0.35
116
1487
84
516
1.71
4.73
2.6
2.5
33.2
33.1
u/l
0.02
71
435
31
137
2.32
4.44
1.1
1.4
—
—
—
0
0
31
137
2.32
4.44
1.1
1.4
—
—
—
0
0
267
2159
1.38
4.07
3.6
3.4
—
—
—
0
0
158
1170
1.45
3.95
5.5
4.5
1.0
1.0
kg/l
0.66
27
176
461
5091
0.72
3.94
4.6
5.1
6.1
6.1
mmol/l
0.21
421
4533
145
1059
1.47
3.89
2.9
3.0
1.9
1.1
e6/l
0.95
66
645
138
1001
1.47
3.83
3.0
3.2
4.8
2.1
e6/l
0.69
59
593
159
1187
1.44
3.80
4.0
4.2
373.3
294.4
ng/l
0.18
136
1010
7
9
7.84
3.56
1.4
1.9
27.2
14.7
umol/l
—
7
9
213
2612
0.73
3.45
3.8
4.2
—
—
—
0
0
211
1682
1.37
3.40
3.5
3.4
0.4
0.6
e6/l
1.70
149
1297
9
257
0.34
3.36
1.4
1.8
—
—
—
0
0
9
19
4.78
3.24
1.0
1.1
—
—
—
0
0
105
1435
0.68
3.21
1.6
1.7
1.5
1.3
mmol/l
0.91
89
1158
10
28
3.61
3.20
1.0
1.0
—
—
—
0
0
50
795
0.60
3.08
1.2
1.3
13.1
37.3
iu/ml
4.24
15
257
47
757
0.59
3.04
1.3
1.3
1.5
12.6
u/ml
3.80
13
256
9
21
4.33
3.00
1.1
1.2
—
—
—
0
0
41
235
1.79
2.99
2.3
3.1
4.1
4.4
pmol/l
0.83
32
204
168
2093
0.74
2.91
2.7
3.2
784.6
1862.7
ng/l
11.53
140
1816
42
685
0.59
2.86
3.0
4.2
17.2
36.1
ug/l
0.58
37
577
25
125
2.04
2.74
2.6
2.8
32.4
33.1
umol/l
0.06
18
102
115
1491
0.73
2.54
2.2
2.9
8012.5
9262.0
umol/l
0.08
85
1252
163
1304
1.33
2.49
1.6
1.8
461.0
15067609.6
pmol/l
1.06
132
1042
53
346
1.58
2.43
1.6
1.4
—
—
—
0
0
28
482
0.56
2.36
1.4
1.3
—
—
—
0
0
180
2168
0.77
2.35
2.8
2.8
136.1
155.1
ug/l
0.62
163
1942
31
181
1.75
2.19
1.1
1.2
—
—
—
0
0
0
58
0.00
2.04
0.0
1.7
—
—
—
0
0
104
1326
0.75
2.03
2.4
3.1
1.0
0.8
ug/l
0.39
80
919
54
764
0.68
1.98
2.9
4.9
34.0
32.3
%
0.43
37
492
64
873
0.71
1.92
2.2
2.5
21.5
21.8
%
0.06
56
748
121
970
1.30
1.81
1.5
2.0
29.6
29.9
s
0.19
114
940
6
151
0.39
1.78
1.3
1.4
—
—
—
0
0
95
739
1.33
1.77
11.7
7.8
—
—
—
0
0
6
18
3.35
1.75
1.2
1.2
—
—
—
0
0
13
255
0.50
1.73
3.9
3.4
214.8
15877.9
u/ml
—
6
217
518
5450
0.81
1.68
10.1
11.3
24.0
24.9
u/l
0.59
490
5219
8
32
2.52
1.60
2.1
2.5
—
—
—
0
0
7
159
0.43
1.56
1.6
1.6
—
—
—
0
0
59
440
1.37
1.46
1.6
1.6
—
—
—
0
0
34
491
0.68
1.43
2.6
3.6
1.2
1.2
mmol/l
0.10
29
429
79
993
0.77
1.40
2.2
2.5
11.9
12.2
umol/l
0.13
68
924
72
915
0.76
1.39
2.2
2.5
2.2
2.3
g/l
0.20
59
854
8
161
0.49
1.37
1.6
1.4
—
—
—
0
0
14
247
0.56
1.36
1.4
2.8
—
—
—
0
0
536
5588
0.82
1.36
28.0
25.2
131.1
133.3
g/l
2.69
519
5480
5
17
2.95
1.36
2.4
4.2
27.2
31.2
umol/l
—
5
12
32
459
0.68
1.31
2.1
3.1
74.8
58.8
ml/min/173m2
0.90
12
201
9
173
0.51
1.30
1.6
1.5
—
—
—
0
0
62
476
1.33
1.30
3.1
3.9
77.6
90.3
ng/l
0.68
49
416
5
18
2.79
1.28
1.2
1.2
—
—
—
0
0
75
594
1.29
1.27
2.9
3.7
2.4
2.0
mmol/l
0.50
63
468
151
1296
1.21
1.27
2.7
2.7
7.4
4.7
e6/l
0.67
135
1141
8
36
2.24
1.24
2.4
1.3
—
—
—
0
0
7
141
0.49
1.22
1.3
1.2
—
—
—
0
0
58
446
1.33
1.21
1.6
2.1
375.4
376.3
nmol/l
0.01
50
404
8
154
0.51
1.15
1.3
1.9
—
—
—
0
0
0
36
0.00
1.14
0.0
1.4
—
—
—
0
0
0
36
0.00
1.14
0.0
1.4
—
—
—
0
0
23
152
1.53
1.10
1.2
1.2
—
—
—
0
0
23
153
1.52
1.07
1.2
1.2
—
—
—
0
0
111
943
1.21
1.04
2.6
3.3
0.8
0.8
mmol/l
0.77
99
882
8
150
0.53
1.04
1.9
1.5
—
0.4
—
0
30
71
575
1.26
1.04
3.4
2.6
8.3
6.7
ug/l
0.20
57
499
121
1398
0.84
1.01
2.3
2.4
—
—
—
0
0
9
157
0.57
0.99
1.0
1.5
1.3
1.2
g/l
—
9
149
405
3821
1.14
0.98
4.4
3.8
14.7
15.1
pmol/l
1.75
370
3369
0
31
0.00
0.96
0.0
1.2
—
1.2
—
0
12
8
42
1.92
0.88
1.0
1.1
—
2.7
nmol/l
—
0
8
27
364
0.73
0.83
2.7
2.9
0.8
0.3
e6/l
0.34
27
355
6
114
0.52
0.83
1.0
1.2
—
—
—
0
0
6
115
0.52
0.83
1.7
1.8
38.5
42.9
nmol/l
—
6
107
9
150
0.59
0.79
1.0
1.5
0.3
0.2
g/l
—
9
142
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
88
754
1.19
0.79
6.1
7.3
1.0
1.3
mmol/l
0.17
66
592
0
26
0.00
0.78
0.0
1.1
—
101.8
—
0
19
0
26
0.00
0.78
0.0
1.1
—
33.3
—
0
19
0
26
0.00
0.78
0.0
1.4
—
—
—
0
0
5
96
0.52
0.78
1.0
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
4.8
—
—
—
0
0
66
554
1.21
0.74
5.1
7.0
1.4
1.4
mmol/l
0.21
61
532
212
2289
0.89
0.68
4.4
5.5
2.4
3.7
ug/l
1.38
174
2024
532
5467
0.89
0.67
23.6
20.5
4.0
4.0
mmol/l
4.07
512
5306
45
546
0.81
0.66
1.3
1.3
—
—
—
0
0
86
749
1.17
0.66
6.3
7.3
5.0
5.1
kpa
0.27
81
718
86
750
1.17
0.65
6.3
7.2
11.2
11.6
kpa
0.30
81
720
8
127
0.63
0.64
1.9
3.5
789.3
2330.2
u/ml
—
8
119
54
641
0.83
0.64
4.4
3.4
—
—
—
0
0
16
222
0.71
0.62
1.8
3.9
60.1
90.9
mg/l
0.43
11
183
16
222
0.71
0.62
1.8
4.0
26.1
51.6
mg/l
1.14
11
186
0
20
0.00
0.60
0.0
2.0
—
—
—
0
0
0
20
0.00
0.60
0.0
2.0
—
16.6
—
0
10
532
5455
0.89
0.59
23.8
20.4
139.7
139.6
mmol/l
0.20
512
5298
0
22
0.00
0.59
0.0
2.3
—
1012.5
—
0
22
179
1658
1.11
0.55
2.9
3.2
34.5
32.6
u/l
0.16
164
1581
30
370
0.80
0.53
1.7
2.2
11.2
12.5
nmol/l
0.34
21
317
6
96
0.62
0.52
1.2
1.3
—
—
—
0
0
6
100
0.60
0.52
2.3
5.7
—
190.3
—
0
15
29
233
1.26
0.51
9.0
3.7
1.5
1.4
mmol/l
0.39
29
227
6
40
1.50
0.51
1.5
1.3
—
—
—
0
0
6
40
1.50
0.51
1.5
1.3
—
—
—
0
0
275
2608
1.09
0.51
4.6
4.0
0.0
0.0
estimate
0.00
29
492
293
3075
0.92
0.51
7.9
8.7
4.8
4.2
e9/l
2.05
244
2670
258
2442
1.09
0.50
2.7
2.3
—
—
—
0
0
28
226
1.25
0.48
1.6
1.6
—
—
—
0
0
18
137
1.32
0.47
2.1
2.3
135.0
126.8
g/l
0.57
12
99
25
200
1.26
0.47
1.3
1.3
—
—
—
0
0
85
942
0.89
0.44
1.2
1.2
1.5
1.4
u/ml
0.05
19
224
9
129
0.69
0.43
1.1
1.5
—
—
—
0
0
5
32
1.57
0.42
1.4
1.2
—
—
—
0
0
5
32
1.57
0.42
1.4
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
15
194
0.77
0.41
1.5
1.7
—
100.0
—
0
9
0
17
0.00
0.40
0.0
2.2
—
—
—
0
0
0
17
0.00
0.40
0.0
1.2
—
9.2
—
0
17
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
382
3942
0.93
0.40
3.3
4.2
12.9
14.5
mm/h
1.22
343
3586
12
160
0.75
0.40
1.6
2.5
54.8
105.6
ug/min
—
7
95
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
15
193
0.77
0.39
1.1
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
2.5
—
100.8
—
0
19
174
1844
0.92
0.38
4.0
4.6
22.2
21.5
%
0.22
83
955
8
112
0.71
0.37
1.1
1.1
—
13.2
—
0
8
5
37
1.35
0.37
1.0
1.4
—
—
—
0
0
9
70
1.29
0.36
1.2
1.3
—
—
—
0
0
5
76
0.66
0.36
1.0
1.2
—
—
—
0
0
10
134
0.74
0.35
1.5
1.4
—
—
—
0
0
6
87
0.69
0.33
1.0
1.1
—
—
—
0
0
317
3067
1.06
0.32
4.0
3.2
50.3
56.9
u/l
0.54
294
2797
169
1781
0.93
0.32
2.7
2.5
50.0
57.1
u/l
2.43
157
1640
271
2610
1.06
0.32
5.8
5.5
0.0
0.0
estimate
0.00
31
484
7
53
1.32
0.31
1.4
1.2
—
—
—
0
0
21
177
1.19
0.27
1.8
3.3
0.0
0.0
g/l
0.00
15
161
11
139
0.79
0.27
1.5
1.7
—
—
—
0
0
35
393
0.88
0.26
3.4
4.0
2.3
1.9
mmol/l
0.27
24
307
29
254
1.15
0.25
1.7
1.8
—
—
—
0
0
13
159
0.81
0.25
1.2
1.4
—
—
—
0
0
273
2649
1.05
0.24
4.6
4.1
0.0
0.0
estimate
0.00
30
478
21
180
1.17
0.24
1.8
3.3
0.0
0.0
g/l
0.00
15
162
22
190
1.16
0.23
1.8
3.2
0.0
0.0
g/l
0.50
16
172
50
545
0.91
0.23
1.5
3.1
65.9
65.8
g/l
0.02
39
493
152
1455
1.06
0.22
5.8
4.3
0.0
0.0
estimate
0.50
27
468
11
135
0.81
0.22
1.4
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
12
0.00
0.21
0.0
3.3
—
126.5
—
0
12
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
2.3
—
0
6
345
3376
1.04
0.21
5.5
4.9
6.9
6.8
mmol/l
0.51
318
3190
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
75
797
0.93
0.20
4.5
5.5
1.0
1.0
mmol/l
0.93
66
739
6
52
1.16
0.19
1.3
1.7
—
—
—
0
0
6
52
1.16
0.19
1.3
1.8
—
—
—
0
0
6
52
1.16
0.19
1.3
1.8
—
—
—
0
0
430
4233
1.04
0.19
6.3
7.7
80.1
81.1
u/l
0.14
400
3937
6
53
1.13
0.18
1.3
1.1
103.8
52.3
u/l
—
6
39
7
59
1.19
0.18
1.7
1.3
39.1
30.2
iu/l
—
7
50
23
258
0.89
0.18
1.7
2.9
—
—
—
0
0
23
258
0.89
0.18
1.7
2.9
7.2
7.6
g/l
0.49
15
186
23
257
0.89
0.17
1.7
2.9
4.2
3.7
g/l
0.38
15
179
113
1177
0.95
0.16
1.7
1.7
1.5
1.4
mg/l
0.13
88
932
6
76
0.79
0.15
1.7
1.5
—
—
—
0
0
6
80
0.75
0.15
2.2
2.8
—
592.7
—
0
10
6
80
0.75
0.15
2.3
3.8
—
—
—
0
0
157
1522
1.04
0.15
2.5
2.2
3.1
3.2
mg/l
0.10
137
1274
9
81
1.11
0.15
1.2
1.4
—
—
—
0
0
220
2149
1.03
0.14
2.2
2.2
77.7
79.1
nmol/l
0.28
192
1860
241
2358
1.03
0.14
4.5
4.1
26.9
46.3
ng/l
4.52
186
1830
33
305
1.09
0.14
3.9
2.4
0.7
0.7
%
0.45
33
295
8
98
0.81
0.13
1.0
1.1
—
—
—
0
0
12
138
0.87
0.13
1.0
1.4
—
—
—
0
0
22
239
0.92
0.10
1.8
2.9
9.4
10.4
g/l
0.67
14
201
472
4680
1.03
0.10
5.5
4.7
2.2
2.0
mu/l
0.27
426
4139
22
203
1.09
0.09
1.8
3.0
40.2
36.7
g/l
2.18
14
170
5
46
1.09
0.09
1.2
1.4
—
—
—
0
0
10
87
1.15
0.09
1.5
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
227
0.92
0.09
2.5
2.4
0.5
0.4
u/ml
—
10
133
5
61
0.82
0.08
2.6
1.7
—
—
—
0
0
5
61
0.82
0.08
1.0
3.3
8.5
6.1
nmol/l
—
5
61
5
62
0.81
0.08
1.8
2.5
—
—
—
0
0
23
216
1.07
0.07
1.7
3.3
0.6
1.3
g/l
0.47
15
185
13
142
0.91
0.06
1.3
1.5
—
—
—
0
0
55
567
0.97
0.06
4.5
7.1
11.1
11.2
mmol/l
0.03
46
536
438
4403
0.99
0.05
22.3
18.9
39.2
38.6
%
0.75
273
2775
14
150
0.93
0.04
2.6
2.7
7.9
7.9
kpa
0.04
14
135
200
2019
0.99
0.04
5.1
4.4
—
—
—
0
0
300
2981
1.01
0.04
4.5
6.3
12.2
12.0
umol/l
0.09
276
2832
32
311
1.03
0.02
3.9
3.4
25.3
25.1
mmol/l
0.09
32
304
517
5158
1.01
0.02
19.4
17.0
29.1
26.5
mg/l
0.94
429
4173
23
238
0.97
0.02
1.7
3.0
3.0
3.2
g/l
0.89
15
183
11
103
1.07
0.02
2.6
1.6
—
—
—
0
0
10
107
0.93
0.02
1.4
1.3
—
—
—
0
0
36
352
1.02
0.01
5.9
9.6
24.1
24.7
mmol/l
0.33
31
331
411
4103
1.00
0.00
23.4
21.0
13.8
13.9
%
0.74
396
4014
10
102
0.98
0.00
1.2
1.6
—
—
—
0
0
24
242
0.99
0.00
1.0
1.1
55.7
127.3
iu/ml
—
8
83
64
638
1.00
0.00
2.4
3.0
10.5
9.4
umol/l
0.15
52
571
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
54
0.93
0.00
1.0
1.9
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
86.7
—
0
7
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
12.0
—
0
5
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
105.4
—
0
9
5
57
0.88
0.00
1.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
6
66
0.91
0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
8.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
3.4
—
84.5
—
0
8
7
79
0.88
0.00
1.6
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_ATROPHCIRCUM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_ATROPHCIRCUM | 3.807 [3.24, 4.47] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.335 |
During the follow-up period (1.1.1998 — 31.12.2019), 1496 out of 2867 females with G6_ATROPHCIRCUM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_ATROPHCIRCUM | 3.818 [3.16, 4.61] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.052 |
During the follow-up period (1.1.1998 — 31.12.2019), 1262 out of 2230 males with G6_ATROPHCIRCUM died.
Mortality risk
Mortality risk for people of age
years, who have G6_ATROPHCIRCUM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.352% | 0.706% |
| 5 | 2.162% | 4.74% |
| 10 | 5.576% | 11.668% |
| 15 | 10.637% | 21.832% |
| 20 | 18.658% | 34.354% |
Relationships between endpoints
↥Index endpoint: G6_ATROPHCIRCUM – Circumscribed brain atrophy
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data